Yolk Sac Tumor
11 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Thalidomide Combined With Chemotherapy in the Treatment of Relapsed or Refractory Yolk Sac Tumor (NCT06470464) | Shandong First Medical University | 2021-11-11 |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors (NCT04377932) | Baylor College of Medicine | 2021-08-08 |
| Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors (NCT05103631) | Baylor College of Medicine | 2021-06-17 |
| Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children (NCT06341998) | Shandong First Medical University | 2020-06-01 |
| Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors (NCT02375204) | Alliance for Clinical Trials in Oncology | 2015-08-06 |
Track Yolk Sac Tumor automatically
Every clearance here is in the API, with alerts when new ones post.